Analyze Diet
Virology2024; 597; 110164; doi: 10.1016/j.virol.2024.110164

Role of pseudotyped viruses in understanding epidemiology, pathogenesis and immunity of viral diseases affecting both horses and humans.

Abstract: In this review, we explore how pseudotyped viruses (PVs) are being applied to the study of viruses affecting both humans and horses. For the purposes of this review, we define PVs as non-replicative viruses with the core of one virus and the surface protein(s) of another and encapsulating a reporter gene such as luciferase. These 'reporter' PVs enable receptor-mediated entry into host cells to be quantified, and thus can be applied to study the initial stages of viral replication. They can also be used to test antiviral activity of compounds and measure envelope protein-specific antibodies in neutralisation tests.
Publication Date: 2024-06-28 PubMed ID: 38959722DOI: 10.1016/j.virol.2024.110164Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Review
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This paper reviews how pseudotyped viruses (PVs) assist in studying viruses that infect both horses and humans, focusing on their use in understanding viral entry, disease mechanisms, immune responses, and antiviral testing.

Introduction to Pseudotyped Viruses

  • Pseudotyped viruses are engineered viruses with a core from one virus and the surface proteins from another.
  • They carry a reporter gene, such as luciferase, which allows researchers to easily detect and quantify virus entry into cells.
  • These viruses are non-replicative, meaning they cannot reproduce, offering a safer way to study viral entry without handling fully infectious viruses.

Applications in Epidemiology

  • PVs enable measurement of how effectively viruses bind and enter host cells, allowing insights into transmissibility and receptor usage.
  • Because PVs can mimic multiple viral envelope proteins, they can be used to compare different viral strains or species and their potential to infect horses and humans.
  • This contributes to understanding cross-species transmission risks and the epidemiological spread of zoonotic viruses.

Contributions to Understanding Pathogenesis

  • By focusing on the entry phase of infection, PVs help elucidate the mechanisms viruses use to invade host cells.
  • This knowledge can highlight critical steps in viral lifecycle that might be targeted for therapeutic intervention.
  • PVs allow study of viral envelope proteins’ role in disease development without full viral replication, reducing biosafety risks.

Role in Immunity and Neutralisation Testing

  • The reporter gene in PVs facilitates sensitive detection of neutralising antibodies against viral envelope proteins.
  • Neutralisation tests with PVs can evaluate vaccine efficacy or immune responses in infected or vaccinated horses and humans.
  • PVs offer a standardized and safe platform for serological studies across multiple virus types affecting both species.

Utility for Antiviral Testing

  • PVs can be employed to screen candidate antiviral compounds for their ability to block viral entry.
  • This approach accelerates identification of potential drugs without requiring high-containment facilities needed for live virus cultures.
  • The presence of a measurable reporter gene allows rapid quantitative assessment of antiviral efficacy.

Summary

  • Pseudotyped viruses are valuable tools bridging study of viruses shared between horses and humans.
  • They improve safety, facilitate detailed study of viral entry and immune response, and enhance antiviral discovery efforts.
  • This review highlights their growing importance in veterinary and human virology research.

Cite This Article

APA
Sedgwick RL, ElBohy O, Daly JM. (2024). Role of pseudotyped viruses in understanding epidemiology, pathogenesis and immunity of viral diseases affecting both horses and humans. Virology, 597, 110164. https://doi.org/10.1016/j.virol.2024.110164

Publication

ISSN: 1096-0341
NlmUniqueID: 0110674
Country: United States
Language: English
Volume: 597
Pages: 110164
PII: S0042-6822(24)00185-5

Researcher Affiliations

Sedgwick, Rebecca L
  • One Virology - WCGVR, School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, UK.
ElBohy, Ola
  • One Virology - WCGVR, School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, UK.
Daly, Janet M
  • One Virology - WCGVR, School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, UK. Electronic address: janet.daly@nottingham.ac.uk.

MeSH Terms

  • Horses
  • Animals
  • Humans
  • Virus Diseases / immunology
  • Virus Diseases / virology
  • Virus Diseases / veterinary
  • Horse Diseases / virology
  • Horse Diseases / immunology
  • Horse Diseases / epidemiology
  • Viruses / immunology
  • Viruses / genetics
  • Viruses / pathogenicity
  • Viruses / classification
  • Virus Replication
  • Virus Internalization
  • Antibodies, Viral / immunology

Grant Funding

  • Wellcome Trust

Conflict of Interest Statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Citations

This article has been cited 2 times.
  1. Ramos-Cela M, Forconi V, Antonelli R, Manenti A, Montomoli E. Exploring the Use of Viral Vectors Pseudotyped with Viral Glycoproteins as Tools to Study Antibody-Mediated Neutralizing Activity. Microorganisms 2025 Jul 31;13(8).
  2. Singh M, Shanmukha S, Eldesouki RE, Harraz MM. FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry. Front Pharmacol 2025;16:1537912.
    doi: 10.3389/fphar.2025.1537912pubmed: 40166473google scholar: lookup